Abstract
Sildenafil is the most prescribed oral agent for patients with erectile dysfunction (ED). Vardenafil is a new phosphodiesterase type 5 (Pde-5) inhibitor that was approved by the US Food and Drug Administration last year to treat patients with ED of various causes. Both of these Pde-5 inhibitors have vasodilating properties and effects on blood pressure (BP), and like nitrates, they work through the nitric oxide cyclic guanosine monophosphate pathway. The aim of this study was to investigate the influence of these Pde-5 inhibitors on BP and heart rate (HR) in normotensive men with ED by a crossover comparison. Thirty-five patients with ED were enrolled to evaluate and compare the effect of sildenafil (50 mg) and vardenafil (10 mg) on BP and HR. At the screening (baseline [B]) visit, sitting systolic blood pressure (B-SBP), diastolic blood pressure (B-DBP), and HR were measured. We performed a multiple administration for both drugs and, therefore, multiple measurements of BP and HR changes, 3 doses a week, on alternate days, late in the afternoon, and on an empty stomach. B-SBP, B-DBP, and HR were recorded before each 50-mg sildenafil dosing and after 30, 60, 120, and 240 minutes. Data were averaged over the 4 time points and com...Continue Reading
References
Jun 1, 1990·The Journal of Urology·M A VickersN Weidner
Jun 1, 1997·Urology·R C RosenA Mishra
Jul 2, 1998·International Journal of Impotence Research·A MoralesI H Osterloh
Feb 6, 1999·Journal of the American College of Cardiology·M D CheitlinR M Zusman
Mar 17, 1999·The American Journal of Cardiology·R M WallisP Ellis
Mar 17, 1999·The American Journal of Cardiology·G JacksonM J Allen
Aug 9, 2001·International Journal of Impotence Research·H PorstT Bandel
Mar 16, 2002·International Journal of Impotence Research·A F De RoseG Carmignani
May 7, 2002·Urology·Yoram VardiIlan Gruenwald
Dec 12, 2002·Journal of the American College of Cardiology·Udho ThadaniPavur Sundaresan
Citations
May 6, 2005·BJU International·Maurits M BarendrechtMartin C Michel
Jun 7, 2005·Expert Opinion on Drug Safety·Thorsten Reffelmann, Robert A Kloner
Feb 28, 2007·Vascular Health and Risk Management·Thorsten Reffelmann, Robert A Kloner
Feb 16, 2008·Circulation Research·Tatiana M VinogradovaEdward G Lakatta
Jul 25, 2009·International Journal of Clinical Practice·W Dinsmore
Jul 6, 2015·Journal of Endocrinological Investigation·R PofiE Giannetta
Mar 28, 2008·Current Hypertension Reports·Lorenzo GhiadoniStefano Taddei
Feb 29, 2008·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Konstantinos KontarasZenon S Kyriakides
Aug 21, 2009·Naunyn-Schmiedeberg's Archives of Pharmacology·Alberto J KaumannMaría Luisa Vargas
Nov 14, 2019·British Journal of Pharmacology·Nikolaos TzoumasDavid J Webb
Jul 27, 2005·BJU International·Culley C Carson, Tom F Lue
Jan 1, 2009·Diabetes/metabolism Research and Reviews·Alin StirbanDan Ziegler
Aug 4, 2006·Current Hypertension Reports·L Michael Prisant
Nov 11, 2008·Journal of Endocrinological Investigation·G CoronaM Maggi
Jun 9, 2006·International Journal of Impotence Research·E R SchwarzS Rosanio
Jun 24, 2010·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Manoli VourvahisJayvant Heera
Aug 6, 2015·International Urology and Nephrology·Baris AfsarMehmet Kanbay
Nov 27, 2008·BJU International·François Giuliano
Nov 7, 2006·The Journal of Urology·Tuomo NieminenMika Kähönen